• Alvotech recently amended its credit agreement with funds managed by GoldenTree Asset Management and other lenders to add a US$75 million term loan facility bearing 12.50% interest and maturing on December 31, 2027, building on a US$165 million equity raise completed in June 2026 and bringing total new available capital to US$240 million.
• This combination of fresh equity, additional debt capacity and continued backing from long-term partner GoldenTree reinforces Alvotech’s ability to fund its biosimilar pipeline, upcoming product launches and global commercial expansion.
• Next, we’ll explore how this expanded US$75 million term loan facility and overall US$240 million capital access affect Alvotech’s investment narrative.

Find 41 companies with promising cash flow potential yet trading below their fair value.

Alvotech Investment Narrative Recap

To own Alvotech, you have to believe its expanding biosimilar portfolio and global partnerships can translate a complex pipeline into durable cash generation, despite regulatory and pricing pressures. The new US$75 million term loan, combined with the recent equity raise, directly addresses near term liquidity concerns, but does not remove the key short term catalyst and risk: timely regulatory clearances for major biosimilars and any associated delays in milestone driven revenue.

Among recent developments, the May 2026 FDA Form 483 for Alvotech’s Reykjavik facility stands out as particularly relevant. The expanded US$240 million capital access gives the company more room to address inspection findings, sustain R&D and manage launch preparation costs while it works through resubmissions. How quickly and cleanly Alvotech resolves these regulatory items could influence both the timing of new product launches and the volatility of milestone revenues.

Yet beneath this improved funding, investors should be aware that the combination of high interest debt and already heavy leverage could...

Alvotech's narrative projects $1.0 billion revenue and $223.4 million earnings by 2029.

Uncover how Alvotech's forecasts yield a $13.83 fair value, a 286% upside to its current price.

Exploring Other Perspectives

Some of the lowest ranked analysts focus on the same regulatory execution risk but pair it with concern about high debt, even while assuming revenue of about US$982.5 million and US$82.7 million in earnings by 2029, so their more cautious view could shift as the new US$75 million facility and wider US$240 million capital access play through future regulatory milestones.

Explore 5 other fair value estimates on Alvotech - why the stock might be worth just $4.00!

Decide For Yourself

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Alvotech research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Alvotech research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Alvotech's overall financial health at a glance.

Curious About Other Options?

Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:

• AI is about to change healthcare. These 39 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Explore 26 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
• Rare earth metals are the new gold rush. Find out which 31 stocks are leading the charge.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.